Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Study of the Combination Regorafenib With PF-03446962 in Patients With Refractory Metastatic Colorectal Cancer (REGAL-1 Trial)

NCT02116894 is registered in ClinicalTrials.gov with Duke University as lead sponsor.

NCT NCT02116894
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02116894 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Study of the Combination Regorafenib With PF-03446962 in Patients With Refractory Metastatic Colorectal Cancer (REGAL-1 Trial)
Lead sponsor
Duke University
Phase
Phase 1
Overall status
Completed
Start date
August 31, 2014
Completion date
May 31, 2016
Enrollment
11 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

colorectal cancer